Navigation Links
LX4211 for Diabetes Shown to Reduce Fasting and Post-Prandial Blood Sugar in Healthy Subjects
Date:9/13/2011

le metabolic effects in healthy subjects, together with the safety profile observed to date, suggest that LX4211 could be considered earlier in the diabetes treatment paradigm, perhaps including the potential treatment of pre-diabetes in patients with impaired glucose tolerance or impaired fasting glucose (IGT/IFG)."

About the Clinical Trial

The clinical trial was designed to assess the effect of different LX4211 dose schedules relative to meal time  in healthy subjects when taken as a single daily dose (400 mg) or a split dose (200 mg twice daily).  Subjects were randomized to LX4211 in an ordered sequence to assess the pharmacodynamic effects of different dosing times, ranging from 1 hour prior to meals to immediately prior to meals.  Pharmacodynamic effects, include urinary glucose excretion, fasting plasma glucose, insulin, PYY and GLP-1 (total and active) were assessed at multiple time points during the 12-day dosing period.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug programs in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's clinical development of LX4211, including characterizations of the results of and projected timing o
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
2. Phase 2 Trial of LX4211 Demonstrates Significant and Rapid Improvements in Multiple Parameters in Type 2 Diabetic Patients
3. Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
4. Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients
5. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
6. Lexicon Presents LX4211 Clinical Data at European Association for the Study of Diabetes Annual Meeting
7. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
8. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
9. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
10. Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
11. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... North America,s leading business partnering event ... 30 th edition of its annual conference at the ... 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... specialty chemical companies will take part in the conference, which ...
(Date:1/14/2014)... Emergency Critical Care, a LifeCentre partner practice, located at 165 Fort ... first in Loudoun County to receive a ... M. Barnes , Medical Director, is a well-seasoned veterinarian of more ... , are avid scuba divers. "As altitude skiers and hikers, we ...
(Date:1/14/2014)... 14, 2014 Equashield ( http://www.equashield.com ... drugs, today announced that it has achieved 60% ...   Equashield,s closed systems reduce the ... and other medical professionals who prepare and administer ...
Breaking Medicine Technology:Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Equashield's Sales Grow by 60% in 2013 2
...  Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) ... granted a positive opinion for conditional approval from ... Products for Human Use ("CHMP"). Based on the ... authorization for Pixuvri should be granted by the ...
...  A new look at the three most highly regarded ... of its kind to consider long-term cost and quality ... prostatectomy surgery and brachytherapy to be less expensive and ... the treatment of prostate cancer . ...
Cached Medicine Technology:European Medicines Agency's Committee For Medicinal Products For Human Use Issues Positive Opinion For Conditional Approval On Marketing Authorization Application For Pixuvri™ 2European Medicines Agency's Committee For Medicinal Products For Human Use Issues Positive Opinion For Conditional Approval On Marketing Authorization Application For Pixuvri™ 3European Medicines Agency's Committee For Medicinal Products For Human Use Issues Positive Opinion For Conditional Approval On Marketing Authorization Application For Pixuvri™ 4European Medicines Agency's Committee For Medicinal Products For Human Use Issues Positive Opinion For Conditional Approval On Marketing Authorization Application For Pixuvri™ 5Prostate Cancer Treatment Options Go Head-to-Head 2Prostate Cancer Treatment Options Go Head-to-Head 3
(Date:4/22/2014)... DC (April 22, 2014) The International Communication ... 22-26 in Seattle, Washington. The theme of the ... means in a networked and digital society. , ... attended by over 2,200 Communication scholars representing over ... scholarly international communication conference in the world. This ...
(Date:4/22/2014)... German . , ... their mode of action is complex: In low concentrations ... while at high concentrations they can cause "oxidative stress", ... redox signaling unfolds in single cells and organelles in ... jointly by the teams of LMU Professor Martin Kerschensteiner ...
(Date:4/22/2014)... CITY)A computational tool developed at the University of Utah ... gene mutations in three separate cases, U of U ... in The American Journal of Human Genetics . ... identifies undiagnosed illnesses and unknown gene mutations by analyzing ... code for genes are made, in individual patients and ...
(Date:4/22/2014)... researchers have demonstrated the first size-based form of ... membranes of living cells. This unique physical approach ... critical to whether a cell lives or dies, ... obtained through conventional microscopy. , "We,ve developed membrane-embedded ... to both probe and manipulate membrane assemblies, including ...
(Date:4/22/2014)... parallel with modern man ( Homo sapiens ), there were ... side by side, such as Neanderthals and the recently discovered ... survived. What was it in our genetic makeup that gave ... known about our unique genetic makeup as distinguished from our ... we are the only species among them ,to survive. Even ...
Breaking Medicine News(10 mins):Health News:International Communication Association to hold Annual Conference in Seattle, Washington 2Health News:Neuroimaging: Live from inside the cell 2Health News:Applying math to biology: Software identifies disease-causing mutations in undiagnosed illnesses 2Health News:Applying math to biology: Software identifies disease-causing mutations in undiagnosed illnesses 3Health News:First size-based chromatography technique for the study of livi 2Health News:First size-based chromatography technique for the study of livi 3Health News:What gave us the advantage over extinct types of humans? 2
... Coalition for,Pulmonary Fibrosis (CPF) announced the appointment of ... has more than 25 years of experience,overseeing all ... in,leadership for non-profit foundations such as the CPF. ... including expanding CPF fundraising,capabilities and driving its overall ...
... Assume Key Management Posts as Senior Vice Presidents, ... (NYSE: AGP ) today announced the hiring ... key management positions: Linda,Whitley-Taylor has been named Executive ... AMERIGROUP as Senior Vice President, Senior,Litigation Counsel; and ...
... Robert A Weinberg is the first recipient of the science ... Georg and Eva Klein. The prize is awarded in person ... 29 January 2008. The prizewinner, who is to be a ... to Karolinska Institutet in Stockholm for two weeks to give ...
... In today,s volatile business,environment, unforeseen market shifts ... product forecasts, sales strategies and,development plans. By ... a high-functioning Competitive Intelligence group,can alert organizations ... warn,them about potential external risks., Competitive ...
... Collaboration with Harvard Medical International Provides ... Vital Global Health Information, BALTIMORE, Jan. 29 ... reach of their groundbreaking MEDEX,360m partnership with the launch ... and leisure travelers., Like the original MEDEX 360m ...
... side by side to equal the width of a human ... for administering medicines and other therapeutic agents to patients. But ... after they discharge their medical payloads has been a major ... months tracking the tiny tubes inside mice, have found some ...
Cached Medicine News:Health News:CPF Appoints Mishka Michon Chief Executive Officer 2Health News:AMERIGROUP Names Linda Whitley-Taylor as Executive Vice President, Associate Services 2Health News:AMERIGROUP Names Linda Whitley-Taylor as Executive Vice President, Associate Services 3Health News:Building and Sustaining Impactful Competitive Intelligence Organizations for Pharma 2Health News:MEDEX / Harvard Partnership Now Offers Affordable, New Intelligence to Individual Business & Leisure Travelers 2Health News:New nanotube findings by Stanford researchers give boost to potential biomedical applications 2Health News:New nanotube findings by Stanford researchers give boost to potential biomedical applications 3
MDI will work with your facility to determine the best interim lab to fit your needs and your site....
... large number of mobile, modular and transportable ... fleet. The labs are typically leased to ... The Cath Lab Leasing Company allows hospitals ... upgrading existing equipment, initiating a new service ...
... PowerSuite holmium laser combines excellent cutting, ... virtually bloodless procedures. It is also ... gall bladder stones of all compositions, ... tool. Because its laser light is ...
... technology has allowed for perfecting mini-invasive endoscopic ... various pathologies with a considerable social impact. ... reducing the post-operatory times and represents a ... in all hospital structures.,DEKAs family of Nd:YAG ...
Medicine Products: